免責事項:アナリストのレーティングおよび目標株価は、情報提供のみを目的としてLSEG Data & Analyticsが提供するものであり、投資助言を構成するものではありません。
Transmedics Group Incの注目ポイント
強みリスク
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
企業コードTMDX
企業名Transmedics Group Inc
最高経営責任者「CEO」Dr. Waleed H. Hassanein, M.D.
ウェブサイトhttps://www.transmedics.com/
よくある質問
Transmedics Group Inc(TMDX)の現在の株価はいくらですか?
Transmedics Group Inc(TMDX)の現在の株価は146.000です。
Transmedics Group Incのティッカーシンボルは何ですか?
Transmedics Group IncのティッカーシンボルはTMDXです。
Transmedics Group Incの52週高値はいくらですか?
Transmedics Group Incの52週高値は145.500です。
Transmedics Group Incの52週安値はいくらですか?
Transmedics Group Incの52週安値は55.000です。
Transmedics Group Incの時価総額はいくらですか?
Transmedics Group Incの時価総額は4.99Bです。
Transmedics Group Incの純利益はいくらですか?
Transmedics Group Incの純利益は35.46Mです。
Transmedics Group Inc (TMDX) の現在の評価は「買い」、「ホールド」、「売り」のどれですか?
アナリストによると、Transmedics Group Inc(TMDX)の総合評価は買いで、目標株価は143.417です。
Transmedics Group Inc (TMDX) の1株当たり利益(EPS TTM)はいくらですか?
Transmedics Group Inc(TMDX)の1株当たり利益(EPS TTM)は2.707です。